Literature DB >> 21725855

Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas.

Xiao-Bing Wang1, Xiao-Ying Tian, Yang Li, Bin Li, Zhi Li.   

Abstract

Macrophage migration inhibitory factor (MIF) plays a critical role in tumorigenesis. We aim to examine the association of MIF with tumor recurrence and survival of gliomas, and to determine whether MIF is a valuable prognostic predictor for glioma patients. The expression of MIF and interleukin 8 (IL-8) was evaluated in 36 high-grade gliomas (20 glioblastoma multiforme, 13 anaplastic astrocytoma, and 3 anaplastic oligoastrocytoma) and 32 low-grade gliomas (18 fibrillary astrocytoma, 5 pilocytic astrocytoma, 5 oligodendroglioma, 3 ependymoma and 1 pleomorphic xanthoastrocytoma) by immunostaining. Intratumoral microvessel density (IMD) of tumors in relation to immunostainings and clinicopathological factors were analyzed statistically as well as the follow-up data of patients. High expression of both MIF (58.8%) and IL-8 (52.9%) was significantly associated with high-grade gliomas and increased microvessels in tumors, but only high expression of MIF was closely related to tumor recurrence (P = 0.001). High expression of IL-8 exhibited a close correlation with high expression of MIF in tumors (P = 0.001). Histological grading, high expression of MIF and IL-8 correlated with patients' overall survival in univariate analysis. However, only histological grading and MIF expression exhibited a relationship with survival of patients as independent prognostic factors of glioma by multivariate analysis; the hazard ratios were 28.012 (P = 0.001) and 11.782 (P = 0.001), respectively. Elevated production of MIF in glioma tumor cells may contribute to tumor recurrence and a worse prognosis. MIF may serve as an independent predictive factor for prognosis of glioma patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725855     DOI: 10.1007/s11060-011-0640-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  38 in total

1.  Modulation of MDR-1 gene by MIF and GSTpi with drug resistance generation in hormone independent prostate cancer.

Authors:  D-S Yu; J C Lin; D S Hsieh; S Y Chang; C F Lee
Journal:  Arch Androl       Date:  2006 Jul-Aug

Review 2.  Role of MIF in inflammation and tumorigenesis.

Authors:  Jan-Philipp Bach; Birgit Rinn; Bernhard Meyer; Richard Dodel; Michael Bacher
Journal:  Oncology       Date:  2008-09-15       Impact factor: 2.935

3.  Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.

Authors:  Daniel J Caruso; Adrienne J K Carmack; Vinata B Lokeshwar; Robert C Duncan; Mark S Soloway; Bal L Lokeshwar
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.

Authors:  H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen
Journal:  Oncogene       Date:  2007-02-19       Impact factor: 9.867

5.  Co-elevated expression of hepatocyte growth factor and Interleukin-8 contributes to poor prognosis of patients with primary nasopharyngeal carcinoma.

Authors:  Li-Qiong Xie; Li-Juan Bian; Zhi Li; Yang Li; Ying-Jie Liang
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

Review 6.  Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?

Authors:  Carsten Nieder; Nicolaus Andratschke; Nicole Wiedenmann; Raymonde Busch; Anca L Grosu; Michael Molls
Journal:  Strahlenther Onkol       Date:  2004-07       Impact factor: 3.621

7.  Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression.

Authors:  C Munaut; J Boniver; J-M Foidart; M Deprez
Journal:  Neuropathol Appl Neurobiol       Date:  2002-12       Impact factor: 8.090

8.  Necrosis as a prognostic factor in glioblastoma multiforme.

Authors:  F G Barker; R L Davis; S M Chang; M D Prados
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

9.  Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.

Authors:  Monika Nagy; Daniela Schulz-Ertner; Marc Bischof; Thomas Welzel; Holger Hof; Jürgen Debus; Stephanie E Combs
Journal:  Tumori       Date:  2009 May-Jun

10.  HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.

Authors:  P J Maxwell; R Gallagher; A Seaton; C Wilson; P Scullin; J Pettigrew; I J Stratford; K J Williams; P G Johnston; D J J Waugh
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

View more
  16 in total

1.  Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner.

Authors:  Jelena Põlajeva; Tobias Bergström; Per-Henrik Edqvist; Anders Lundequist; Anna Sjösten; Gunnar Nilsson; Anja Smits; Michael Bergqvist; Fredrik Pontén; Bengt Westermark; Gunnar Pejler; Karin Forsberg Nilsson; Elena Tchougounova
Journal:  Mol Oncol       Date:  2013-09-18       Impact factor: 6.603

2.  Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.

Authors:  Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-25       Impact factor: 4.553

3.  PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.

Authors:  Isabella Venza; Maria Visalli; Cinzia Fortunato; Manuela Ruggeri; Simona Ratone; Maria Caffo; Gerardo Caruso; Concetta Alafaci; Francesco Tomasello; Diana Teti; Mario Venza
Journal:  Epigenetics       Date:  2012-10-10       Impact factor: 4.528

4.  Brain miffed by macrophage migration inhibitory factor.

Authors:  Nic E Savaskan; Günter Fingerle-Rowson; Michael Buchfelder; Ilker Y Eyüpoglu
Journal:  Int J Cell Biol       Date:  2012-09-03

5.  Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Authors:  Ramona Schulz; Natalia D Marchenko; Lena Holembowski; Günter Fingerle-Rowson; Marina Pesic; Lars Zender; Matthias Dobbelstein; Ute M Moll
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

6.  Increased expression of macrophage migration inhibitory factor and DJ-1 contribute to cell invasion and metastasis of nasopharyngeal carcinoma.

Authors:  Xiao-Juan Pei; Tong-Tong Wu; Bin Li; Xiao-Ying Tian; Zhi Li; Qing-Xu Yang
Journal:  Int J Med Sci       Date:  2013-12-22       Impact factor: 3.738

7.  HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Authors:  R Schulz; F Streller; A H Scheel; J Rüschoff; M-C Reinert; M Dobbelstein; N D Marchenko; U M Moll
Journal:  Cell Death Dis       Date:  2014-01-02       Impact factor: 8.469

8.  ISO-66, a novel inhibitor of macrophage migration, shows efficacy in melanoma and colon cancer models.

Authors:  Kyriaki Ioannou; Kai Fan Cheng; Gregg V Crichlow; Anastasios I Birmpilis; Elias J Lolis; Ourania E Tsitsilonis; Yousef Al-Abed
Journal:  Int J Oncol       Date:  2014-07-22       Impact factor: 5.650

9.  Association between inflammatory infiltrates and isolated monosomy 22/del(22q) in meningiomas.

Authors:  Patrícia Henriques Domingues; Cristina Teodósio; Álvaro Otero; Pablo Sousa; Javier Ortiz; María del Carmen García Macias; Jesús María Gonçalves; Ana Belén Nieto; María Celeste Lopes; Catarina de Oliveira; Alberto Orfao; Maria Dolores Tabernero
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  Macrophage migration inhibitory factor and stearoyl-CoA desaturase 1: potential prognostic markers for soft tissue sarcomas based on bioinformatics analyses.

Authors:  Hiro Takahashi; Robert Nakayama; Shuhei Hayashi; Takeshi Nemoto; Yasuyuki Murase; Koji Nomura; Teruyoshi Takahashi; Kenji Kubo; Shigetaka Marui; Koji Yasuhara; Tetsuro Nakamura; Takuya Sueo; Anna Takahashi; Kaname Tsutsumiuchi; Tsutomu Ohta; Akira Kawai; Shintaro Sugita; Shinjiro Yamamoto; Takeshi Kobayashi; Hiroyuki Honda; Teruhiko Yoshida; Tadashi Hasegawa
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.